enGene Therapeutics Inc. (ENGN)
NASDAQ: ENGN · Real-Time Price · USD
1.770
+0.010 (0.57%)
Jul 31, 2026, 3:15 PM EDT - Market open
enGene Therapeutics Stock Forecast
Stock Price Forecast
According to 10 analysts polled by S&P Global, enGene Therapeutics stock has a consensus rating of "Hold" and an average price target of $3.29. The average 1-year stock price forecast is 85.88% higher than the current stock price, while the lowest is $2.00 (+12.99%) and the highest is $5.00 (+182.49%).
Price Target: $3.29 (+85.88%)
Analyst Consensus: Hold
Price Target
Chart* Price targets were last updated on Jun 16, 2026.
Analyst Ratings
The average analyst rating for enGene Therapeutics stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 2 | 2 | 2 |
| Buy | 3 | 3 | 3 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 8 | 6 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 1 | 1 |
| Total | 11 | 11 | 11 | 11 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Sell Downgrades n/a | Sell | Downgrades | n/a | n/a | Jun 18, 2026 |
| Guggenheim | Guggenheim | Hold Maintains n/a | Hold | Maintains | n/a | n/a | Jun 16, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Maintains $6 → $4 | Buy | Maintains | $6 → $4 | +125.99% | Jun 16, 2026 |
| Wells Fargo | Wells Fargo | Hold Reiterates $2 | Hold | Reiterates | $2 | +12.99% | Jun 16, 2026 |
| UBS | UBS | Hold Maintains $9 → $2 | Hold | Maintains | $9 → $2 | +12.99% | May 14, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
6.17M
EPS This Year
-1.73
from -2.29
EPS Next Year
-1.40
from -1.73
EPS and Forward PE are based on non-GAAP adjusted numbers.